• Kyowa Kirin maintains its forecast for the fiscal year net income at 63.00 billion yen, although it falls short of the estimated 66.01 billion yen.
• The company maintains its core operating profit outlook at 85.00 billion yen.
• Kyowa Kirin’s estimated net sales are at 473.00 billion yen, slightly above the estimated 472.14 billion yen.
• The company continues to forecast a dividend of 58.00 yen per share, slightly below the estimate of 58.40 yen.
• It’s R&D expenses are projected to reach 100.0 billion yen, a tad more than the estimated 99.49 billion yen.
• The company’s Q1 results reveal that net income rose by 15% year-on-year to 14.63 billion yen, albeit a bit lower than the estimated 15.1 billion yen.
• Net sales for Q1 grew by 13% year-on-year to 105.57 billion yen, a tad below the estimated 107.56 billion yen.
• Research and Development expenses increased by a significant 40% year-on-year to 23.32 billion yen.
• Core operating profit increased by 2.5% year-on-year to 17.40 billion yen.
• This growth in core operating profit was due to an increase in gross profit thanks to an increase in overseas revenue and technology licensing revenue. This was despite a notable increase in research and development expenses.
• There are 5 buy ratings, 7 hold ratings, and 0 sell ratings for the company’s stock.
• These comparisons are based on company-provided data and original disclosures.
Kyowa Kirin Co Ltd on Smartkarma
“`html
Analyst coverage on Kyowa Kirin Co Ltd on Smartkarma indicates a bullish sentiment. Tina Banerjee‘s recent report titled “Kyowa Kirin (4151 JP): Recent Portfolio Strengthening Initiatives to Accelerate Long-Term Growth” highlights the company’s partnership with Bridgebio for infigratinib in Japan and the enrollment of the first patient in a Phase 2 trial for tivozanib eye drops for DME. Despite the positive developments, higher R&D expenses are expected to impact the company’s near-term profit. Kyowa Kirin’s flagship drug Crysvita continues to exhibit steady growth post-launch, with the 2023 results surpassing expectations, although the increased R&D spending is forecasted to have a negative effect on the 2024 operating profit.
“`
This reflects Tina Banerjee‘s insights on Kyowa Kirin Co Ltd and their recent activities as published on Smartkarma.
A look at Kyowa Kirin Co Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Looking ahead, Kyowa Kirin Co Ltd appears to have a promising long-term outlook based on its Smartkarma Smart Scores assessment. With solid scores of 3 for both value and dividend, the company demonstrates a good financial standing and commitment to rewarding its investors. Furthermore, scoring a 4 in growth and momentum, Kyowa Kirin Co Ltd shows potential for future expansion and positive market trends. Additionally, a resilience score of 5 indicates the company’s ability to weather economic downturns and challenges, adding to its overall stability.
As a pharmaceutical company, Kyowa Kirin Co Ltd focuses on developing, manufacturing, and marketing a range of innovative products, including proteins produced using genetic recombination technology. Their portfolio includes essential medications such as anti-anemia agents and other glycoproteins. This strong foundation, coupled with the favorable Smart Scores, suggests that Kyowa Kirin Co Ltd is well-positioned for sustained growth and success in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
